Just a couple chart dumps from last two days and bit of FA.
On a macro level global markets are going through a mini-distribution phase. But given the epic bounce we've had off lows this is likely a small correction from the overheated rally.
XJO (07/05/19): Likely correct its way down a little towards support after bumping its head on highs.
NIFTY (08/05/19): Sold off stronger last session after that break of support (blue line). Also bumped its head on highs after an aggressive rally.
XEC (07/05/19): Held itself up strongly yesterday. Specs are still showing continued strength regardless. Been an incredibly strong trend, and likely will test that major blue line above at some stage.
DOW (08/05/19): Decent distribution going on here. Another one which has has a vicious bounce, strong aggressive rally and will need to correct itself a little bit. Still overall picture remains quite bullish from the recent rally.
Nikkei (09/05/19): Weekly chart on Japans market. Quite likely to move back down to trendline/support for a soft landing.
Specs: Regardless of a slight global pullback, specs continue operating independently on their own accord. Couple breakout setups; LON
FAR
ABR (weekly), Daily also looks strong.
Fundamentals: OCC +360% intraday. Definitely a sign of a market that can perform, moves like that can fire up an entire sector or entire market lol. OCC in the cell regenerative sector to repair CNS damage. Had 4 patients repair musculoskeletal and PNS function after 24months, which is a big outcome sitting at $50M MC at this stage.
I remember watching an interview from Tony Locantro couple weeks ago speaking about how bullish he is on cell regeneration space and its going to be the next big thing on markets with USA leading the way. We've had one huge runner yesterday, now it will be interesting to see if the space gets dragged up. PNV is your leader that's done 88% this year at $700M MC. OCC sitting at $50M MC and I do suspect it could go higher ST although not my tea buying these moves. EX1 (which is Tony's deal) and RGS both directly focused on the same space both sitting circa $20M MC. NSB is one I'll keep eye on for a move. $8M MC, $5M cash so practically priced as a shell has a drug for CNS and neuroregenerative capabilities and cell regeneration for optic nerve with Leedman on the board. "The Emtin peptides are synthetic peptides of 14 amino acids in size that are based on specific amino acid sequences identified within the MTII protein structure. Of these peptides, EmtinB is the lead candidate shown to closely mimic the neuroprotective and neuroregenerative ability of MTII in both in-vitro (cultured cellbased) and in-vivo (animal-based) preclinical studies."
Another sector that's had very little chatter here is milk; have a look at these milk co. charts its gone absolutely insane.
Essentially driven by an underlying strong spot price on milk powders which has also gone strong.
KTD also copped a serious move lately made $819K revenue last quarter sitting at $90M MC.
As for my picks; @Mundo122 has done a good review of JAT above. It's one im watching.
AU8 also is moving into a cashflow neutral business from their recent daigou acquisition, they also sell milk powders sitting at $50M MC. They've put a big target aiming for $100M revenue FY20, have a partnership with JD. Lot of placement selling going on but most looks to have cleared.
LON is my pick, other than chart looking good. Its been beaten down to nothing, back to raise price. Has Maggie Beer joining the board for their expansion. In discussion with Chinese for export agreements, developing a biodynamic-organic milk range which will be in trial next month. The same organic milk range that sent BUB exponential recently. Also has the same McBain managing director who pioneered BAL to over $1B MC Just a quick comparison; LON: $40M MC, H1 gross profit $10M BUB: $800M MC, H1 gross profit $3.8M
(20min delay)